Thiotepa-associated cardiomyopathy during blood or marrow transplantation: Association with the female sex and cardiac risk factors  by Alidina, Amyn et al.
INTRODUCTION 
High-dose thiotepa (TT) is used with a variety of agents
as part of conditioning regimens for autologous and allo-
geneic blood or marrow transplantation (BMT) for solid
tumor and hematologic malignancies. Solid tumors tre a t e d
with BMT include breast cancer, testicular cancer, malig-
nant melanoma, central nervous system malignancies, and
n e u roblastoma [1–8]. Hematologic malignancies include
leukemia, lymphoma, and multiple myeloma [3,9–11]. Con-
ditioning regimens include TT in combination with busul-
fan (Bu), cyclophosphamide (Cy), carboplatin (Cb), etopo-
side (VP), melphalan, ifosfamide, mitoxantrone, epirubicin,
or total body irradiation (TBI) [1–14]. Known toxicities of
TT include myelosuppression, mucositis, hepatic and neu-
rological dysfunction. Cardiac damage as seen with Cy
[15–18] has not been described with the use of TT. We
o b s e rved that some patients receiving high-dose TT- c o n-
taining regimens developed unexplained card i o m y o p a t h y.
To look for instances of unexplained cardiomyopathy within
the first 30 days after transplantation, we reviewed BMT
patient charts at our institution over the past 6 years.
METHODS
A total of 439 allogeneic and autologous BMTs for hema-
tologic disorders or solid tumor malignancies were perf o rm e d
on 430 patients between January, 1991, and July, 1997. We
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ABSTRACT
Thiotepa (TT) has not been re p o rted to cause card i o m y o p a t h y, whereas cyclophosphamide (Cy)-related card i o m y-
opathy is well characterized. To search for cases of acute onset cardiomyopathy associated with TT, we re t ro s p e c-
tively reviewed 171 patients who received TT-containing conditioning regimens for blood or marrow transplantat i o n
(BMT). Nine of 171 patients (5.3%) developed clinical congestive heart failure in the post-BMT period. The media n
time to onset of heart failure was 15 days after BMT (range 5–30). The median pre-BMT left ventricular ejection frac-
tion (LVEF) was 50% (range 42–65%) as determined by two-dimensional echocardiogram, or gated blood pool scan.
At the time of cardiomyopathy onset, LVEF was 30%. Six patients died of causes unrelated to heart failure. All
a ffected patients who developed congestive heart failure following administration of TT had some evidence of
c a rdiac dysfunction prior to transplantation. Significant risk factors for the development of cardiomyopathy included
low pre - B M T- LVEF and female sex—particularly in females receiving allogeneic transplantation. The incidence of
congestive heart failure with TT-containing regimens was similar to the incidence using other regimens with and
without Cy. The mean time to clinical evidence of TT-associated cardiomyopathy was longer than the mean time
re p o rted with Cy. We recommend caution in using high-dose TT-containing regimens for patients with histories of
c a rdiac dysfunction.
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examined the case-histories of 171 patients who underw e n t
allogeneic (n559) or autologous (n5112) BMT with TT-
containing conditioning regimens. In this analysis, patients
who received TT/Cy were excluded. Three conditioning re g-
imens were used: 104 patients received TT/TBI (TT, 300
m g / m2 i . v. daily on days –5 and –4 [total dose 600 mg/m2] and
TBI 1000 or 1200 cGy in 200 cGy fractions on days –3,–2,
and –1); 66 patients received TT/Cb (TT, 450 mg/m2 i . v.
daily on days –6 and –5 [total dose 900 mg/m2]; and Cb, 1600
m g / m2 continuous i.v. infusion over 96 hours from days –6 to
–3); one patient received TT at a dose of 200 mg/m2 i . v. daily
f rom days –7 to –5 (total dose 600 mg/m2). The 171 cases
comprised 42% non-Hodgkin’s lymphoma, 16% Hodgkin’s
disease, 15% multiple myeloma, and 14% breast cancer.
In our second analysis comparing the incidence of
T T-associated cardiomyopathy with other regimens, we
investigated a single transplant for each of 430 patients. For
nine patients who had two transplants, only the last trans-
plant was selected for analysis. Of the 171 patients in the TT
g roup from the first analysis, 167 were selected by this
p rocess. Table 1 lists the distribution of regimens, including:
TT/Cy (TT, 300 mg/m2 i . v. daily on days –6 to –4 [total
dose 900 mg/m2] and Cy, 60 mg/kg i.v. daily on days –6 to –4
[total dose 180 mg/kg]) (n558); VP/Cy/TBI [19] (n51 2 0 ) ;
Bu/TBI (Bu, 1 mg/kg p.o. every 6 hours for eight doses on
days –5 and –4 [total dose 8 mg/kg] and TBI 1000–1200
cGy in 200 cGy fractions on days –3, –2, and –1) (n54 2 ) ;
Bu/Cy [20] (n510); Cy/carmustine/cisplatin [21] (n59 ) ;
CyBVP [22] (n57); melphalan/TBI [23] (n56); Cy [24]
( n53 ) ; melphalan [25] (n53); Cy/TBI [26] (n52 ) ;
Cy/antithymocyte globulin/TBI [27] (n51); VP/Cy [28]
( n51); and VP/TBI [29] (n51). 
Blood or marrow cells were infused on day 0. All
patients received antimicrobial prophylaxis with fluconazole
and acyclovir. Patients undergoing allogeneic BMT received
graft-vs.-host disease (GVHD) prophylaxis with cyclosporine
and methotrexate [30], cyclosporine and methylpre d n i s o l o n e
[31], cyclosporine, OKT3, and methylprednisolone [32], or
cyclosporine, methotrexate, and methylprednisolone [33]. 
We looked for clinical evidence of grade II and III car-
diomyopathy within the first 30 days of BMT using Bearm a n
criteria [34]. All patients were examined daily for signs and
symptoms of congestive heart failure (CHF) using the follow-
ing regimen: daily measurement of oxygen saturation; exami-
nation for symptoms of dyspnea, chest pain or palpitations, or
signs of ankle edema or pulmonary congestion; and testing
for drop in the left ventricular ejection fraction (LVEF) as
d e t e rmined by 2 D-echocardiogram or gated blood pool scan.
Excluded from the analysis were patients who developed viral
m y o c a rditis or multisystem organ failure from other initiating
events such as sepsis. All timepoints were calculated from day
of infusion of hematopoietic stem cells (day 0).
Statistical tests of independence between categorical
variables were perf o rmed using Fisher’s exact test (SAS
Institute, Cary NC). Logistic re g ression was used to evalu-
ate the prognostic value of a percentage variable on a bina-
ry outcome. Testing was perf o rmed at a significance level
of 0.05.
RESULTS
In our initial analysis of patients developing card i o m y-
opathy from TT-containing preparative regimens, we exclude d
those patients who also received Cy as part of their re g i m e n .
Nine of 171 patients (5.3%) developed TT- a s s o c i a t e d
c a rdiomyopathy as manifested by signs and symptoms of
CHF and a drop in LV E F. None of these nine patients
received a second transplant. Four patients received two
transplants (n5167). Characteristics of these patients who
developed cardiomyopathy are listed in Table 2. The median
time of onset of CHF was day 15 after BMT (mean of 16,
range 5–30) (Table 3). The median LVEF at the time of
development of cardiomyopathy was 30%. The median
d e c rease from pre- to post-BMT LVEF was 23% (mean
d e c rease of 26%, range 17–40%). All nine patients in our
study had pre-BMT evidence of mild cardiac dysfunction
( Table 4) that included electro c a rdiogram changes (n55), his-
t o ry of treated lymphomatous pericardial effusion (n51 ) ,
bicuspid aortic valve (n51), and patent foramen ovale (n51 ) .
The latter two findings were at postmortem analysis. Thre e
patients received prior mediastinal radiation therapy, and
t h ree patients received prior doxorubicin doses $300 mg/m2.
Four of the nine patients (44%) who developed card i o m y o p at h y
had a low LVEF (,50%) prior to transplant. Eighteen of 162
patients (11.1%) who did not develop cardiomyopathy had a
low pretransplant LV E F, which was a risk factor for the devel-
opment of TT- related cardiomyopathy (p 5 0.02). Congest i v e
Table 1. Preparative regimens
n Regimen
120 Etoposide/cytoxan/total body irradiation
103 Thiotepa/total body irradiation
63 Thiotepa/carboplatin
58 Thiotepa/cytoxan
42 Busulfan/total body irradiation
10 Busulfan/cytoxan
34 Other regimens*
*One is thiotepa only; 23 are Cy-regimens as outlined in Methods.
Nine of 430 cases had two transplants at our institution; the second transplant
is included in this table.
Table 2. Characteristics of patients who developed TT-associated CHF
Graft
UPIN Age Sex Disease type Regimen
940208 39 F ALL Allo TT/Cb
960372 24 M HD Allo TT/Cb
940161 54 F NHL Allo TT/TBI
940184 61 F AML Allo TT/TBI
970423 33 F AML Allo TT/TBI
960349 44 F NHL Allo TT/TBI
970385 54 F Breast Ca Auto TT/Cb
940206 47 F Breast Ca Auto TT/Cb
960356 51 F Breast Ca Auto TT/Cb
ALL, acute lymphoblastic leukemia; Allo, allogeneic; AML, acute myeloid
leukemia; Auto, autologous; Ca, cancer; HD, Hodgkin’s disease; F, female;
M, male; NHL, non-Hodgkin’s lymphoma; TT/Cb, thiotepa/carboplatin;
TT/TBI, thiotepa/total body irradiation, UPIN, unique patient identifica-
tion number.
324
h e a rt failure was observed in 10.2% of patients who re c e i v e d
an allogeneic BMT (6/59) and in only 2.7% of autologous
BMT patients (3/112), however this observation was not
s i g n i ficant (p 5 0.07). Eight of the nine cases of CHF were
females. Sex was a significant independent risk factor for
development of CHF (p 5 0.04), with 8/89 females develop-
ing CHF compared to 1/82 males. Female patients who
received allogeneic BMT with a TT-containing re g i m e n
w e re at a higher risk of developing CHF (five patients devel-
oped CHF among the 22 females who received an allogeneic
BMT vs. one patient among the 37 males who received an
allogeneic BMT) (p 5 0.02). The percentage of CHF in
patients treated with either of the TT-conditioning re g i m e n s
was not statistically diff e rent: four of 104 patients (3.9%) who
received TT/TBI; and 5/66 (7.6%) patients who re c e i v e d
TT/Cb developed CHF (p 5 0.31) (Table 2). The tre a t m e n t
of CHF included inotropic support, diuretics, antiarrh y t h-
mics, and pre- and afterload reducing agents. All patients
re c o v e red f rom CHF, but six of nine patients died of noncar-
diac causes within 100 days of transplant (Table 3).
P o s t m o rtem cardiac findings for four patients who
u n d e rwent autopsy were similar to those re p o rted by
D i ndogur et al. for doxorubicin-associated cardiomyopathy
[35]. Grossly, the hearts weighed 360 gm, 430 gm, 440 gm,
and 555 gm, re s p e c t i v e l y. Findings included biventricular
dilatation (n51), biventricular dilatation and patent foramen
ovale (n51), left ventricular mural thrombosis (n51), and
bicuspid aortic valve and aortic root dilatation (n51). Histo-
logic findings included vacuolization and basophilic degen-
eration with or without loss of cross-striations and loss of
myofilamentous bundles (lysis) of myocytes. These histolog-
ic changes multifocally affected all layers of the heart in two
cases, and primarily affected the subendocardial areas in one
case. The fourth case showed no evidence of vacuolization
or cardiac myocytosis, but did show marked interstitial
edema. No evidence of an inflammatory reaction was found
in any of the cases. 
In the entire BMT population, 19 of 430 patients (4.4%)
developed card i o m y o p a t h y. From the cases listed in Table 1,
the incidence in TT-containing conditioning re g i m e n s
(without Cy) was 5.3% (9/167); in Cy-containing re g i m e n s
(without TT), 2.6% (4/153); in TT/Cy, 5.2% (3/58); and in
the remainder of the cases, 5.8% (3/52). There was no statis-
tical diff e rence among these four groups (p 5 0.51). The
median pre-BMT LVEF in patients who developed CHF
was 51% (range 42–69%), and in patients who did not develo p
C H F, the median pre-BMT LVEF was 58% (range 3 5 – 8 4 % ) .
Independent of the regimen, pre-BMT LVEF was pro g n o st i c
for developing CHF (p , 0.001). Sex was also a signific a n t
risk factor for developing card i o m y o p a t h y, re g a rdless of re g i-
men; of 215 females, 7% developed CHF, compared to 1.9%
of 215 males (p 5 0.02). Subset analysis on females re v e a l s
Table 3. TT-Associated cardiomyopathy during BMT
EF EF EF CHF Status
UPIN pre-BMT post-BMT Diff day post-BMT day post-BMT Cause of death
940208 60% 20% 40% 5 D, 167 INF/GVHD
960372 50% 30% 20% 13 D, 153 MOF
940161 48% 30% 18% 24 D, 140 MOF  
940184 48% 25% 23% 8 D, 160 MOF
970423 42% 25% 17% 11 D, 139 MOF
960349 65% 30% 35% 21 A
970385 47% 15% 32% 15 A
940206 59% 35% 24% 24 A
960356 52% 30% 22% 30 D, 151 RF
Mean 52% 27% 26% 16
Median 50% 30% 23% 15
A, alive at day 100; BMT, bone marrow transplantation; CHF, congestive heart failure; D, died; Diff, difference; EF, ejection fraction; GVHD, graft-vs.-host
disease; INF, infection; MOF, multisystem organ failure; RF, respiratory failure; UPIN, unique patient identification number.
Table 4. Prior history of cardiac dysfunction
UPIN Mediastinal RT EKG changes Pre-BMT LVEF ,50% Doxo $300 mg/m 2 Cardiac dysfun
940208 1 – – – LPE
960372 1 1 – 1 BAV
940161 – – 1 – CHF, PFO
940184 – – 1 – None
970423 – – 1 – None
960349 – 1 – – None
970385 – 1 1 – Stable angina
940206 – 1 – 1 None
960356 1 1 – 1 DC
BAV, bicuspid aortic valve; CHF, congestive heart failure; DC, doxorubicin cardiomyopathy; Doxo, doxorubicin; Dysfun, dysfunction; LPE, lymphomatous pericardial effu-
sion; LVEF, left ventricular ejection fraction; PFO, patent foramen ovale; RT, radiation therapy; UPIN, unique patient identification number.
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that breast cancer is not associated with increased risk of
developing CHF. Seven of 78 patients with breast cancer
developed CHF (9%) and eight of 137 females with other
diagnoses developed CHF (6%) (p 5 0.41). As with TT-
containing re gimens, female patients who underwent allo-
geneic transplantation, re g a rdless of regimen, had a signifi-
cantly higher incidence of developing CHF compared with
male patients (eight of 75 females [10.7%] vs. two of 139 males
[1.4%]) (p 5 0.004); this association is not seen with autolo-
gous transplant. Parity data was available on 105 of 215
female patients. No association was found between prior h i s-
t o ry of pregnancy and CHF, re g a rdless of regimen. A seco n d
BMT was associated with an increased risk of CHF re g a rd-
less of regimen. Four of 19 patients (21%) had CHF during
their second or later transplant, compared to 15 of 411
patients (4%) during their first transplant (p 5 0 . 0 0 7 ) .
DISCUSSION 
Onset of CHF during the immediate post-BMT period
is not uncommon. Causes include re g i m e n - related toxicity,
sepsis, cardiac involvement by malignancy, previous history
of anthracycline use, and mediastinal irradiation [36,37]. Cy
is the usual drug that causes re g i m e n - related cardiac toxicity,
with or without TBI. Whereas most patients develop grade I
c a rdiac toxicity, the incidence of grade II or III cardiac toxicit y
is 5–10% with high-dose Cy-containing regimens in the
BMT setting [34]. Higher doses of Cy [17], and a low
p re -BMT LVEF (,50%) [18] are associated with an
i n c reased incidence of card i o m y o p a t h y. When the ejection
fraction is $50%, the frequency of Cy-induced CHF is
,5%, whereas the frequency of CHF is 20–25% when the
ejection fraction is ,50%. Pathologic changes in Cy-
induced cardiomyopathy include myocardial hemorrhage and
n e c rosis, increased heart weight, ventricular wall thickening,
and serosanguinous pericardial effusion with fibrinous peri-
c a rd itis [17]. 
The incidence of re g i m e n - related, acute onset car-
diomyopathy at our institution is 4.4%. Risk factors based
on 430 cases include low pre-BMT LV E F, second trans-
plant, and female sex (in particular females undergoing allo-
geneic transplantation). Female sex as a risk for card i o m y-
opathy has not been re p o rted pre v i o u s l y. Nore t h i s t e ro n e
treatment has been identified as a major risk factor for v e n o -
occlusive disease in women receiving allogeneic transplanta-
tion [38], however, there is no certain etiology re g a rding the
relationship between sex and CHF in our study. We are cur-
rently evaluating other BMT factors in a multivariate analys i s .
We also identified second transplant as a risk factor for car-
d i o m y o p a t h y. The incidence for CHF following second
transplant at our institution is higher than previously re p o rt-
ed [39]; this is likely attributable to diff e rences in the intensi-
ty of conditioning regimens. In patients receiving TT- c o n-
taining regimens, underlying cardiac disease was a pre d i s p o s-
ing factor to the development of CHF. The mean time of
onset of CHF is later than the mean time re p o rted in the lit-
e r a t u re for Cy [15,17]. All patients re c o ve red from CHF,
however four patients developed multiorgan f a i l u re, which
may have arisen as a complication of the initial CHF. 
How can we explain the development of card i o m y o p athy
with TT? A preclinical model of chemotherapy toxicity in
chick embryos demonstrated that TT can induce damage to
cardiac myofibrils and cardiac neural ganglia, similar to the
damage induced by doxorubicin [40]. High doses of TT
with or without TBI may be associated with card i o m y o p athy.
We recommend caution in using high doses of TT for BMT
in patients with pre-BMT evidence of cardiac disease. Alter-
native preparative regimens including the use of less inten-
sive, nonmyeloablative regimens might be considere d ,
p a rticularly for allogeneic BMT [41,42]. 
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